The Randstad, Netherlands
With over two decades of experience in healthcare, I currently serve as the Country Manager Cancer Diagnostics BENELUX at Exact Sciences, now part of Abbott. I lead a dedicated cross-functional team to advance our mission of eradicating cancer through early detection and personalized treatment solutions, while overseeing the region's P&L responsibilities. My expertise encompasses recruiting, finance, and strategic projects (mostly Value and Access driven), which I leverage to support organizational growth and deliver value to stakeholders. My career has been defined by a commitment to improving patient access and delivering innovative healthcare solutions. At Exact Sciences, I contributed to building market access infrastructure and enabling access to transformative diagnostics across multiple markets. With a passion for collaborative leadership, I strive to empower teams and deliver meaningful impact in the field of oncology diagnostics. Posts and profile views are my own and not my employer's.
Exact Sciences was acquired by Abbott and is continuing its mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment In my current role I am leading the team in BeNeLux
Leading the BENELUX Region, responsible and accountable for P&L for BeNeLux, leading a passionate and driven cross functional team. Member of International Commercial Management team Member European Leadership Team
Head of Market Access & Pricing for all ex-US markets, leading a team ensuring all patients can access our products. Built out the Market Access organization with Pricing, Health Policy and Outcomes and Evidence capabilities to a well-integrated business function to maximizing access for Oncotype Dx and become access-ready for future product launches such as Cologuard and Cancerguard Furthermore acted as the (Interim) Market Access Director for Japan from Dec 2022 - Dec 2024 Member of International Commercial Management team Special assignment to build the Indirect Markets Strategy in 2023.
Special assignment as Market Access Head for 7 countries in Northern Europe responsible for patient access to the entire Abbvie portfolio across the region (>1B USD). Additional matrix responsibility for TA oncology (pipeline decision making / input into BD assessments, launching Venclyxto CLL 1L and AML).
In this role I was leading the team responsible for preparing the ground to ensure optimal patient access for Abbvie's Pipeline assets in Hematology & Oncology (~30-40 programs) Responsible for optimal reimbursement conditions for Companion Diagnostics (CDx) associated with Abbvie's product portfolio Supporting Oncology BD&L evaluations
Fast-pace Execution of innovative access solutions to support the WorldWide Launch of Viekirax-Exviera (Ex-US) Leading winning strategy for Maviret, AbbVie's pan-genotype HCV regimen Hybrid Commercial / Access role
Launching YERVOY (ipilimumab) in 2nd line and 1st line through finding innovative solutions with healthcare authorities Pricing & Access strategy for OPDIVO (nivolumab) for multiple indications, including Yervoy+ Opdivo combination therapy SPRYCEL Commercial Policies
- HTA / evidence generation strategies to optimize patient access across EMEA region. Based at R&D HQ Brussels. - Developed HEOR deliverables to support 6 launches across EMEA - Over 25 publications (abstracts / posters / manuscripts) - started as Manager, promoted twice to Associate Director.
Economic Modelling (CEA, BIA) Evidence Synthesis (e.g MTC, Meta -analysis) (Mostly NL) Reimbursement dossier writing and negotiations with authorities